Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022

March 7, 2022 13:00 UTC

COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March:

Cowen 42nd Annual Virtual Health Care Conference

Dates:

 

March 7-9, 2022

Format:

 

1x1 investor meetings

     

Oppenheimer Fireside Chat

Date:

 

March 14, 2022

Time:

 

11:00 a.m. Eastern Time

Title:

 

“AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape”

Presenters:

 

Timothy J. Miller, Ph.D., Chief Executive Officer of Forge Biologics

   

RA Session, II, Chief Executive Officer of Taysha Gene Therapies

   

Rachel Potter, Ph.D., Head of Gene Therapy Research at Sarepta Therapeutics

Moderators:

 

Kevin DeGeeter, Senior Analyst, Biotechnology and Diagnostics

   

Hartaj Singh, Senior Analyst, Biotechnology

     

Oppenheimer 32nd Annual Virtual Healthcare Conference

Dates:

 

March 15-17, 2022

Format:

 

1x1 investor meetings

     

Date:

 

March 17, 2022

Time:

 

10:40 a.m. Eastern Time

Format:

 

Company presentation

Presenter:

 

Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics

Dr. Miller’s Oppenheimer company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at https://www.forgebiologics.com/news/#events.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220307005504/en/

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Source: Forge Biologics

Back to news